James M Gallo

Summary

Affiliation: Temple University
Country: USA

Publications

  1. ncbi request reprint Cells designed to deliver anticancer drugs by apoptosis
    Jianguo Ma
    Department of Pharmacology Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:1382-7. 2002
  2. ncbi request reprint The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:5114-7. 2003
  3. ncbi request reprint Pharmacokinetic model-predicted anticancer drug concentrations in human tumors
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19140, USA
    Clin Cancer Res 10:8048-58. 2004
  4. pmc Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry
    Ping Guo
    School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 43:1789-95. 2007
  5. doi request reprint Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania 19140, USA
    Clin Cancer Res 14:1540-9. 2008
  6. pmc Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
    Qingyu Zhou
    Department of Pharmaceutical Sciences, Temple University, Philadelphia, PA 19140, USA
    Neuro Oncol 11:301-10. 2009
  7. ncbi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
    J Pharmacol Exp Ther 321:265-75. 2007
  8. ncbi request reprint Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models
    Jianguo Ma
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Pharmacol Exp Ther 305:833-9. 2003
  9. pmc Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib
    Shining Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
    Mol Cancer Ther 8:1438-47. 2009
  10. pmc Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, United States
    J Pharm Biomed Anal 51:958-64. 2010

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Cells designed to deliver anticancer drugs by apoptosis
    Jianguo Ma
    Department of Pharmacology Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:1382-7. 2002
    ..Apoptosis-induced drug delivery offers a new avenue for targeted drug delivery research that uses biological control mechanisms...
  2. ncbi request reprint The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:5114-7. 2003
    ..It is concluded that even in the neovasculature of brain tumors, Pgp has the facility to limit drug penetration, although somewhat less so than in normal brain...
  3. ncbi request reprint Pharmacokinetic model-predicted anticancer drug concentrations in human tumors
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19140, USA
    Clin Cancer Res 10:8048-58. 2004
    ..It is believed that this modeling strategy can be used as an aid in the drug development process by providing key insights into drug disposition in tumors and by offering a foundation to optimize drug regimen design...
  4. pmc Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry
    Ping Guo
    School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 43:1789-95. 2007
    ..The method has the advantages of low sample volume, rapid clean-up, and the simultaneous measurement of MTX and 7-OH MTX in plasma and brain tissues allowing detailed PK studies to be completed in individual mice...
  5. doi request reprint Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania 19140, USA
    Clin Cancer Res 14:1540-9. 2008
    ..Thus, the effect of the multitargeted tyrosine kinase inhibitor sunitinib on tumor distribution of temozolomide was investigated to evaluate conditions for optimal combination chemotherapy...
  6. pmc Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
    Qingyu Zhou
    Department of Pharmaceutical Sciences, Temple University, Philadelphia, PA 19140, USA
    Neuro Oncol 11:301-10. 2009
    ..In conclusion, the effect of sunitinib on the brain tumor distribution of TMZ was dose dependent and indicated that optimal tumor exposure was achieved at a lower dose and was associated with the VNI...
  7. ncbi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
    J Pharmacol Exp Ther 321:265-75. 2007
    ..In conclusion, several PK/PD factors contributing to the antitumor activity of the MD TMZ therapy have been identified and form a foundation for further investigations of low-dose TMZ regimens...
  8. ncbi request reprint Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models
    Jianguo Ma
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Pharmacol Exp Ther 305:833-9. 2003
    ..It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected...
  9. pmc Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib
    Shining Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
    Mol Cancer Ther 8:1438-47. 2009
    ..The implementation of the PK/PD equivalent dosing strategy offers a new approach to drug development...
  10. pmc Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, United States
    J Pharm Biomed Anal 51:958-64. 2010
    ..The established method was successfully applied to the characterization of sunitinib disposition in the brain and brain tumor as well as its systemic pharmacokinetics in a murine orthotopic glioma model...
  11. pmc Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma
    Jyoti Sharma
    Department of Pharmaceutical Sciences, Temple University, Philadelphia, PA, USA
    Cancer Res 73:5242-52. 2013
    ..These types of models offer a mechanistic basis to understand tumor heterogeneity as it impacts the activity of anticancer drugs...
  12. ncbi request reprint Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    Clin Cancer Res 13:4271-9. 2007
    ..Our goal was to show how the latter could be achieved for temozolomide, an agent used in the treatment of brain tumors, using an orthotopic brain tumor model in rats...
  13. doi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania 19140, USA
    Pharm Res 29:2499-511. 2012
    ..Na, as a potential chemotherapeutic agent for brain tumors using a series of PK/PD studies, which led to the evaluation of its structural analog, ON013105, a prodrug of the more lipophilic product, ON013100...
  14. doi request reprint Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
    Shining Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    Mol Cancer Ther 7:407-17. 2008
    ..The novel concept of PK/PD equivalent dosing regimens could be applied in drug development and to delineate PG differences in drug activity...
  15. doi request reprint Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model
    Jyoti Sharma
    Department of Pharmaceutical Sciences, Temple University, Philadelphia, Pennsylvania 19140, USA
    J Pharm Sci 101:4100-6. 2012
    ..5 ± 0.20-fold variability in PD. The methods are sufficiently accessible and could be applied to other anticancer drugs and tumor models to obtain greater resolution of intratumoral PKs and PDs...
  16. pmc Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models
    Zhan Wang
    Department of Pharmaceutical Sciences, Temple University, Philadelphia, Pennsylvania, USA
    Drug Metab Dispos 39:2155-61. 2011
    ..The findings confirmed that both Abcc2 and Abcc3 significantly influenced the PK properties of MTX, and depending on the MTX dose and strain, alternate elimination pathways were elicited and saturable...
  17. pmc Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice
    Silpa Nuthalapati
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad Street, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 56:1117-20. 2011
    ..ON01910 exhibited a clearance of 3.61±0.85 l/h/kg and a half life of 8.66±3.30 h at 50 mg/kg dose given I.V...
  18. ncbi request reprint Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry
    Ping Guo
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 798:79-86. 2003
    ..054 to 1.96 microg/ml in brain homogenates. A sensitive and specific assay for paclitaxel has been developed that has the advantages of using small sample sizes, and a single extraction step without solvent evaporation...
  19. ncbi request reprint Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
    Weijing Sun
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 8:3100-4. 2002
    ..Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule...
  20. ncbi request reprint Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice
    Gary D Kruh
    Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Metastasis Rev 26:5-14. 2007
    ..This review will discuss insights into the physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 afforded by investigations of these new mouse models...
  21. ncbi request reprint Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry
    Ping Guo
    Department of Pharmacology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 783:43-52. 2003
    ..07 to 2.5 microgram/ml, and from 0.03 to 1.3 microgram/ml in tumor homogenates. The main advantages of this method compared with earlier methods are the ability to measure intact carboplatin in a sensitive and specific manner...
  22. ncbi request reprint Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support
    Meiyu Shen
    Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:243-50. 2002
    ..In addition, single-sample and two-sample limited sampling models (LSMs) were derived to estimate carboplatin's AUC that could be used in the design of drug dosing regimens...
  23. ncbi request reprint Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry
    Ping Guo
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 809:273-8. 2004
    ..01 to 1 microg/g in brain tissue. The advantage of the method enabled the quantitation of vincristine in multiple plasma samples obtained from a single mouse, which permitted the accurate estimation of its pharmacokinetic properties...
  24. ncbi request reprint Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance
    Jianguo Ma
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Biochem Pharmacol 63:1219-28. 2002
    ....
  25. ncbi request reprint Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage
    Martin G Belinsky
    Medical Science Division, Department of Pathology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer Res 67:262-8. 2007
    ..This is the first demonstration that an ATP-binding cassette transporter can affect in vivo tissue sensitivity towards this class of agents...
  26. pmc In vivo microdialysis for PK and PD studies of anticancer drugs
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
    AAPS J 7:E659-67. 2005
    ....
  27. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
    ..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
  28. pmc Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...
  29. ncbi request reprint Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors
    Giuseppe Trapani
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
    Bioconjug Chem 14:830-9. 2003
    ..A plausible degradation pathway accounting for the available experimental data is presented...